home
“Paranova is playing an important part in stimulation competition in the pharmaceutical market.” Erik B. Pfeiffer
EU medicinal products > Safety and quality

Product safety is Paranova’s number one priority

Paranova Group A/S, via its Scandinavian subsidiaries Paranova Danmark A/S, Paranova Läkemedel and Paranova OY, as well as via its German subsidiary EMRAmed by Paranova’s holding company MPA Pharma, have distributed original medicinal products from other EU countries at attractive prices in their home markets in Denmark, Finland, Germany and Sweden for decades. All Paranova and EMRAmed products correspond to those that are distributed by multinational pharmaceuticals companies in Denmark, Finland, Germany and Sweden and are under constant scrutiny by the responsible national Federal Institute for Drugs and Medical Devices. To guarantee the safety and quality of the medicinal products, for years Paranova Group A/S and MPA Pharma have worked closely with trusted suppliers in EU countries and also conducts extensive quality checks before the products are delivered.

Investing in safety and quality

Paranova was established in 1989, in October 2010 Paranova and Germany’s MPA Pharma signed a cooperation agreement. In Germany, the holding company MPA Pharma acquired EMRAmed in 1992 and henceforth managed the business under that name.

In 2010 MPA Pharma invested further in safety and quality by building a modern refrigerated warehouse of 1,000 square metres. Here, large quantities of reimported and parallel imported medicinal products are repackaged, a process during which the cold chain may not be interrupted. The European Commission is currently preparing to introduce even stricter transportation regulations for medicinal products. We are ready to meet the new requirements thanks to our logistics partners who provide us with temperature-controlled transportation services.

Step by step: Where do EU medicinal products come from?

  • Step 1: ResearchParanova researchers search the databases for medicinal products that are offered in other European countries at a lower price than in Denmark, Finland and Sweden. Thanks to their extensive experience they are able to quickly identify economically promising products.
  • Step 2: NegotiationsOnce an interesting product has been identified, Paranova contacts the foreign wholesaler to order a reference sample and inquire about its availability, which can vary enormously from product to product. The larger Paranova’s range of products, the more attractive it is for foreign wholesalers to offer a mix of more and less popular items.
  • Step 3: LicensingUsing the reference sample Paranova Group A/S applies to the European Medicines Agency (EMA) in London for a licence so Paranova can distribute the product in Denmark, Finland and Sweden. Applications for national licences have to be filed with the national institutes for drugs and medical devices. This process ensures that imported medicinal products are subject to the same licensing regulations as Danish, Finnish and Swedish products – so they are just as safe.
  • Step 4: DesignGraphic designers produce packaging and information leaflets in Danish, Finnish and Swedish for the EU import.
  • Step 5: TransportationParanova’s logistics partner collects the products from the wholesaler in the EU country in question and transports them to Osterburg in Germany and from there to Scandinavia. The vehicles are temperature-controlled to ensure that the cold chain is not interrupted – a vital aspect when dealing with thermosensitive medicinal products.
  • Step 6: RepackagingA lot of the medical products are repackaged at the holding company MPA Pharma’s Osterburg site in Saxony-Anhalt using the specially designed packaging material and leaflets.
  • Step 7: Quality assuranceBetween arrival and departure from the Osterburg plant the medicinal products are subjected to several quality checks. The journey travelled by the products is also carefully documented in case any questions turn up later. This way, Paranova and the holding company MPA Pharma ensure that our customers receive nothing but high-quality products that are in prime condition.
  • Step 8: ListingAs soon as the products are repackaged and quality-checked our sales department adds the article in question to the product range. All new products and prices are included in the national databases, which Danish, Finnish and Swedish wholesalers and pharmacies use to look up and order all available medicinal products, including EU imports.
  • Step 9: DeliveryThe orders that are placed every day by pharmacies via pharmaceuticals wholesalers are prepared and handed over into the care of our logistics partner, which delivers all consignments to customers across Denmark, Finland and Sweden several times a day within 24 hours.
  • Step 10: DistributionBy dispensing EU medicinal products, pharmacies can help to lower the cost of the Scandinavian healthcare system (Existiert eine Abgabequote analog zu der in Deutschland?). Patients, too, appreciate the availability of EU imports because they cost less and their copayments are often lower. Even though imported medicinal products come from further afield – and even though they contain identical active substances –they cost far less than the products sold by multinational corporations in Denmark, Finland or Sweden.